An antibody-drug conjugate targeting the GSTA glycopeptide motif on MUC1 showed potent cancer killing (IC50 0.2-49.4 nM) and dose-dependent tumor inhibition in lung cancer mice without significant toxicity.
IC50 as low as 0.2 nM16A-MMAE ADC targeting MUC1 GSTA glycopeptide neoantigen across multiple cancer cell lines
What the researchers found
16A-MMAE ADC targeting the GSTA glycosite-specific neoantigen peptide of MUC1 showed IC50 of 0.2-49.4 nM against cancer cells and dose-dependent tumor inhibition in vivo at 1 mg/kg minimum effective dose.
Why it matters
MUC1 is overexpressed in many cancers. A glycosite-specific ADC approach could enable personalized cancer treatment based on each tumor's specific glycosylation pattern.
The numbers in context
IC50 0.2-49.4 nM; minimum effective dose 1 mg/kg; no significant toxicity at 3 mg/kg
How the study worked
Preclinical study with in-vitro ADC activity across cancer cell lines, in-vivo xenograft efficacy in NCI-H838 NSCLC mice, and safety evaluation in human MUC1 transgenic mice.
Who was studied
NCI-H838 NSCLC xenograft mice and human MUC1 transgenic mice
What this study cannot tell us
Mouse xenograft model; MUC1 glycosylation varies between patients; small animal numbers; clinical translation requires human safety/efficacy testing.
How to read the evidence
Promising preclinical data with in-vitro potency, in-vivo efficacy, and safety assessment in transgenic mice, but early-stage without clinical data.
When this study was published
Published in 2020; glycosite-specific ADCs represent a growing precision oncology approach.
The bigger picture
This combines glycopeptide neoantigen targeting with ADC technology, creating a precision cancer therapy approach that exploits the unique sugar modifications cancer cells display on their surface proteins.
Questions still open
- How variable is GSTA glycosite expression across patient tumors?
- Could glycosite-specific ADCs be combined with checkpoint immunotherapy?
- Would companion diagnostic testing for MUC1 glycosylation patterns guide patient selection?
Common questions
What is an antibody-drug conjugate?
Why target glycopeptides on cancer cells?
Read the original research
An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer.
Cancer medicine, 9(24), 9529-9540
Citation
Pan, Deng; Tang, Yubo; Tong, Jiao; Xie, Chengmei; Chen, Jiaxi; Feng, Chunchao; Hwu, Patrick; Huang, Wei; Zhou, Dapeng. (2020). An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer.. Cancer medicine, 9(24), 9529-9540. https://doi.org/10.1002/cam4.3554